Clinical bottom line
Artificial intelligence (AI) models are increasingly being developed to predict acute kidney injury (AKI) in hospitalized patients, offering potential for earlier detection and intervention. Recent advances demonstrate that machine learning algorithms can integrate complex clinical data in real time to identify patients at risk of AKI with promising accuracy. However, clinical implementation remains limited by challenges in model generalizability, interpretability, and integration into workflows. Continued validation and refinement are needed before widespread adoption in nephrology practice (Zhang et al., 2025; Dong et al., 2021).
What the evidence shows
Zhang et al. (2025) developed and validated a real-time prediction model for AKI in a large cohort of hospitalized adults, demonstrating robust performance with high sensitivity and specificity across diverse clinical settings. Their model incorporated dynamic laboratory and vital sign data, enabling early risk stratification and potential for timely preventive measures.
Dong et al. (2021) applied machine learning techniques to pediatric critical care patients, showing that AI algorithms could predict AKI onset hours before clinical diagnosis, potentially improving outcomes through earlier intervention.
Zhong et al. (2025) utilized causal deep learning approaches to detect cardiac surgery-associated AKI in real time, validating their model across seven time-series cohorts. Their work highlights the value of integrating temporal data and causal inference to enhance prediction accuracy.
Bajaj et al. (2022) provide a comprehensive review of AI applications in AKI prediction, discussing various algorithms, data sources, and clinical contexts. They emphasize the promise of AI but caution regarding data quality, algorithm transparency, and clinical applicability.
Uchino et al. (2021, 2022) discuss the broader role of AI in predicting kidney function and AKI, underscoring the need for multidisciplinary collaboration to translate AI models into clinical decision support tools.
Caveats and uncertainty
Several AI models for AKI prediction have yet to undergo prospective clinical trials demonstrating improved patient outcomes.
Model performance may degrade when applied to populations or settings different from those used in training.
Interpretability of complex AI models remains limited, potentially hindering clinician trust and adoption.
Data heterogeneity, missingness, and bias pose significant challenges for model development and validation.
Ethical and regulatory considerations around AI deployment in healthcare are evolving.
Notably, two recent AI model deployment studies by Kholboyev et al. (2025) were retracted, underscoring the importance of rigorous validation and transparency.
How this may change practice
AI-driven AKI prediction tools could enable proactive risk stratification and early nephrology consultation, potentially reducing AKI incidence and severity.
Integration with electronic health records may facilitate real-time alerts and personalized care pathways.
Clinicians should remain cautious, critically appraising AI tools and participating in validation studies.
Multidisciplinary teams including nephrologists, data scientists, and informaticians are essential for successful implementation.
Ongoing research should focus on improving model generalizability, interpretability, and clinical impact.